Drug Search Results
More Filters [+]

Cenisertib

Alternative Names: cenisertib, as-703569, as703569, as 703569
Latest Update: 2024-04-26
Latest Update Note: PubMed Publication

Product Description

An orally bioavailable, synthetic, small-molecule multi-Aurora kinase inhibitor with potential antineoplastic activity. Cenisertib selectively binds to and inhibits multiple Aurora kinases (AKs), which may result in the inhibition of cell division and proliferation, and the induction of apoptosis in tumor cells that overexpress AKs.

Mechanisms of Action: AURK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: EMD Serono
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cenisertib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Pancreatic Cancer|Oncology Unspecified|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01097512

P1

Completed

Pancreatic Cancer

2010-07-01

NCT00391521

P1

Completed

Oncology Solid Tumor Unspecified

2010-06-01

NCT01080664

P1

Terminated

Oncology Unspecified|Oncology Hematological Unspecified

2010-03-01

Recent News Events